Amgen, Inc. has had a difficult start to 2021, with Q1 revenues declining 4% thanks to the impact of the pandemic, but its CEO Robert Bradway is confident it can return to growth during the year.
Speaking in a one-to-one at the BIO Digital conference with BIO’s chief executive Michelle McMurry-Heath, Bradway said the company would bounce back quickly.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?